Evidence map›Paper›PMID 41388352›Full record

ReviewACS chemical neuroscience2026

Interplay between CD33 and TREM2 in Alzheimer's Disease: Potential Mechanistic Insights into Microglial Function in Amyloid Pathology.

Elizabeth T Akinluyi, Kei Takahashi-Yamashiro, Meghan G Connolly, Wayne W Poon, Matthew S Macauley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. PreoperativeFrontiers in bioinformatics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elizabeth T AkinluyiDepartment of Chemistry, University of Alberta, Edmonton T6G 2G2, Canada.
Kei Takahashi-YamashiroDepartment of Chemistry, University of Alberta, Edmonton T6G 2G2, Canada.
Meghan G ConnollyDepartment of Chemistry, University of Alberta, Edmonton T6G 2G2, Canada.
Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine 92697, United States.
Matthew S MacauleyDepartment of Chemistry, University of Alberta, Edmonton T6G 2G2, Canada.ORCID 0000-0003-4579-1048

Funding

Cell autonomous and non-cell autonomous phenotypes due to genetic risk for late onset Alzheimers diseaseRF1AG068992 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI POON, WAYNE W · 2021 to 2021
$2.2M
Cell autonomous and non-cell autonomous phenotypes due to genetic risk for late onset Alzheimers diseaseR01AG068992 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI POON, WAYNE W · 2024 to 2025
$1.4M
NIA NIH HHS R01 AG068992NIA NIH HHS RF1 AG068992
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques, tau neurofibrillary tangles, and progressive neuronal loss leading to cognitive decline. With millions affected worldwide, there remains an urgent need for innovative treatment strategies to combat this disease. Genome-wide association studies (GWAS) have identified genes expressed in microglia, the resident immune cells of the brain, as key mediators of AD susceptibility. Among microglial risk genes,

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesMembrane GlycoproteinsMicrogliaReceptors, ImmunologicSialic Acid Binding Ig-like Lectin 3AnimalsBrainHumansPlaque, AmyloidAmyloid beta-PeptidesCD33 protein, humanMembrane GlycoproteinsReceptors, ImmunologicSialic Acid Binding Ig-like Lectin 3TREM2 protein, humanAlzheimer’s diseaseAβ plaqueCD33microgliasialylated glycansTREM2

Identifiers

PMID41388352
PMCPMC13584827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.